New combo therapy aims to tame deadly transplant complication
NCT ID NCT07184853
First seen Jun 26, 2026 · Last updated Jul 08, 2026 · Updated 2 times
Summary
This study tests whether adding etanercept to the standard drug ruxolitinib can better control severe graft-versus-host disease (GVHD) in people who have had a stem cell transplant. GVHD occurs when donor immune cells attack the recipient's body, and current treatments often fail. About 122 participants will be randomly assigned to receive either ruxolitinib alone or ruxolitinib plus etanercept, with the main goal of seeing if the combination leads to a higher response rate after 28 days.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Ruxolitinib and etanercept
- What this could lead to
- If successful, this combination could offer a more effective treatment option for patients with severe graft-versus-host disease that does not respond to steroids, potentially improving survival.
- What could go wrong
- This is a relatively small, early-stage trial (122 participants) and the combination may not prove superior to ruxolitinib alone. There are also risks of increased side effects from adding another immunosuppressant.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CORTICOSTEROID-REFRACTORY SEVERE ACUTE GRAFT-VERSUS-HOST DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Affiliated Hospital of Zhejiang University School of Medicine
RECRUITINGHangzhou, Zhejiang, 310000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a safer dose of an old drug shield vulnerable children from deadly fungal infections?
- Gene analysis may unlock secrets of bone marrow transplant complication
- Aggressive chemo plus stem cell transplant tested for breast cancer
- Herbal extract shows promise for stiff skin and joints in transplant survivors
- Immune-Guided drug timing could cut CMV prevention after transplant
- New drug shows promise in preventing Graft-Versus-Host disease